Key result
Renal denervation significantly reduced mean 24-hour systolic blood pressure from 158 to 147 mm Hg and diastolic blood pressure from 97 to 89 mm Hg over 24 months (p<0.05).
Why the study?
The clinical efficacy of renal denervation in patients with resistant hypertension, type 2 diabetes, and coronary artery disease after endovascular revascularization needed investigation.
Does renal denervation reduce mean 24-hour arterial pressure in patients with resistant hypertension, type 2 diabetes, and coronary artery disease after endovascular revascularization?
Observational (n=75)
No
Does renal denervation reduce mean 24-hour arterial pressure in patients with resistant hypertension, type 2 diabetes, and coronary artery disease after endovascular revascularization?
p-value: p=<0.05
RDN may aid BP and glycemic control in this high-risk group; leaves open effects on events or restenosis.
Aim. To study the clinical efficacy of renal denervation (RDN) in patients with resistant hypertension (RH), type 2 diabetes (T2D) and coronary artery disease (CAD) after endovascular revascularization. Material and methods. The prospective, non-randomized, controlled, single-center study included 75 patients with true RH, T2D and CAD after complete endovascular revascularization. The participants were distributed in a 1:1,5 ratio into the RDN group and the control group. RDN was performed through femoral vascular access with a Spyral catheter (Medtronic, USA). The follow-up period was 24 months. The primary endpoint was the change in mean 24-hour arterial pressure (BP). The secondary endpoint was the assessment of the incidence of adverse cardiovascular and cerebral events. Changes in paraclinical parameters and drug therapy were also assessed. Results. In the RDN group, mean 24-hour systolic BP decreased from 158 [144;167] to 147 [137;156] mm Hg (p<0,05) and diastolic BP from 97 [82;112] to 89 [75;101] mm Hg (p<0,05); glycated hemoglobin — from 7,6 [6,9;8,4] to 6,6 [6,2;7,2]% (p<0,05). In the RDN group, a decrease in the number of antihypertensive drugs taken was noted due to diuretic therapy discontinuation (p<0,05). The rate of major adverse cardiovascular events was 26,7% in the RDN group and 24,4% in the control group. The mean average value of late lumen loss of the stented segment according to quantitative coronary angiographic analysis (qualitative comparative analysis, QCA) was 24,7% in the RDN group and 28,1% in the control group. The incidence of de novo stenosis was 23,3% in the RDN group and 22,2% in the control group. There were no differences between the groups. The glomerular filtration rate in both groups did not change significantly and remained stable. Conclusion. The study results confirm the favorable pleiotropic effects and safety of RDN in polymorbid patients with a combination of RH, T2D and CAD with the total sympathetic nervous system involvement, which offers opportunities for a wider study and implementation of this interventional procedure in clinical practice.
No takes yet. Share an insight, caveat, or question.
Arablinsky et al. (2025) conducted an observational in Resistant hypertension, type 2 diabetes, and coronary artery disease (n=75). Renal denervation vs. Control group was evaluated on Change in mean 24-hour arterial pressure (BP) (p=<0.05). Renal denervation significantly reduced mean 24-hour systolic blood pressure from 158 to 147 mm Hg and diastolic blood pressure from 97 to 89 mm Hg over 24 months (p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: